Skip to main content
Log in

Histone acetylation and disease

  • Published:
Cellular and Molecular Life Sciences CMLS Aims and scope Submit manuscript


Differential acetylation of histones and transcription factors plays an important regulatory role in developmental processes, proliferation and differentiation. Aberrant acetylation or deacetylation leads to such diverse disorders as leukemia, epithelial cancers, fragile X syndrome and Rubinstein-Taybi syndrome. The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders. Current treatment strategies are discussed, which are still mostly limited to histone deacetylase inhibitors such as trichostatin A and butyrate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations


Additional information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Timmermann, S., Lehrmann, H., Polesskaya, A. et al. Histone acetylation and disease. CMLS, Cell. Mol. Life Sci. 58, 728–736 (2001).

Download citation

  • Issue Date:

  • DOI: